Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAN 2021 | Changing perspectives on preventive treatment outcome measures in migraine

Zaza Katsarava • 11 Jun 2021
EAN 2021
Headache

Zaza Katsarava, MD, PhD, MSc, University of Essen, Essen, Germany, discusses preventive treatment outcomes beyond migraine/headache frequency and intensity. Prof. Katsarava highlights the importance of widening outcome measures to consider patient wellbeing, disease burden, and quality of life. Highly efficacious and well tolerated treatments are now available and continue to emerge and thus, treatment expectations are increasing above those of migraine non-specific agents. This interview took place during the European Academy of Neurology 2021 congress.

Disclosures

Prof. Katsarava has received honoraria from Allergan, Lilly, Novartis and TEVA.

More from Zaza Katsarava

How to manage medication overuse headache
2:52
How to manage medication overuse headache
Zaza Katsarava • 11 Jun 2021
An adaptive approach is critical for successful long-term preventive migraine treatment
2:03
An adaptive approach is critical for successful long-term preventive migraine treatment
Zaza Katsarava • 11 Jun 2021
Moving forward with migraine-specific agents: CGRP & PACAP
1:59
Moving forward with migraine-specific agents: CGRP & PACAP
Zaza Katsarava • 11 Jun 2021

Related Videos

PACAP-38 is increased in the tear fluid of patients with migraine
1:50
PACAP-38 is increased in the tear fluid of patients with migraine
Marina Romozzi • 27 Jun 2026
TRIPLE study: triple combination therapy for chronic migraine
2:41
TRIPLE study: triple combination therapy for chronic migraine
Marina Romozzi • 27 Jun 2026
Combination therapy for migraine: anti-CGRP, anti-PACAP, and onabotulinumtoxinA
8:49
Combination therapy for migraine: anti-CGRP, anti-PACAP, and onabotulinumtoxinA
Richard Lipton • 1 Jul 2026
CONFIDENCE: real-world consistency of response to rimegepant for the acute treatment of migraine
5:05
CONFIDENCE: real-world consistency of response to rimegepant for the acute treatment of migraine
Richard Lipton • 1 Jul 2026

Choose your cookie settings

VJNeurology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJNeurology is intended for healthcare professionals